Synovial Fibroblast 3.1: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 1 of 2) - Dataset (ID:20234)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA1931 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | MCP3 | 33.0 | 65 | |
N2586 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | MCP3 | 21.0 | 76 | |
N2586 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | MCP3 | 26.0 | 81 | |
RA1869 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | MCP3 | 213.0 | 61 | |
RA1869 | IL-1 alpha | 100 | ng/mL | 3 | MCP3 | 267.0 | 71 | ||||
N2759 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | MCP3 | 107.0 | 77 | |
N2759 | IL-1 alpha | 100 | ng/mL | 3 | MCP3 | 103.0 | 63 | ||||
RA1931 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | MCP3 | 266.5 | 70 | |
RA1931 | IL-1 alpha | 100 | ng/mL | 3 | MCP3 | 421.0 | 76 | ||||
N2586 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | MCP3 | 194.0 | 85 | |
N2586 | IL-1 alpha | 100 | ng/mL | 3 | MCP3 | 186.0 | 67 | ||||
RA1869 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 3 | MCP3 | 16.0 | 61 | |
RA1869 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 3 | MCP3 | 31.0 | 88 | |
N2759 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 3 | MCP3 | 19.0 | 95 | |
N2759 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 3 | MCP3 | 21.0 | 75 | |
RA1931 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 3 | MCP3 | 17.0 | 81 | |
RA1931 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 3 | MCP3 | 23.0 | 73 | |
N2586 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 3 | MCP3 | 18.0 | 80 | |
N2586 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 3 | MCP3 | 27.0 | 55 | |
RA1869 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 3 | MCP3 | 33.0 | 78 | |
RA1869 | TNF-a | 100 | ng/mL | 3 | MCP3 | 43.5 | 64 | ||||
N2759 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 3 | MCP3 | 23.0 | 72 | |
N2759 | TNF-a | 100 | ng/mL | 3 | MCP3 | 23.0 | 64 | ||||
RA1931 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 3 | MCP3 | 28.0 | 69 | |
RA1931 | TNF-a | 100 | ng/mL | 3 | MCP3 | 32.5 | 48 |